Comment on "Increased risk of second cancers at sites associated with HPV after a prior HPV-associated malignancy, a systematic review and meta-analysis"
Related Experiment Videos
Rama Jayaraj1, Chellan Kumarasamy2
1Clinical Sciences, College of Health and Human Sciences, Charles Darwin University, Ellengowan Drive, Casuarina, NT, 0909, Australia. Rama.Jayaraj@cdu.edu.au.
British Journal of Cancer
|March 27, 2019
Abstract
No abstract available in PubMed .
Related Concept Videos
Articles linked to this work by shared authors, journal, and citation graph.
Lung cancer risk prediction models and asbestos exposure: a validation study on the Western Australia Asbestos Review Program.
Occupational and environmental medicine·2026
Optimized PEGylated paclitaxel and 6-gingerol co-loaded liposomes induce G2/M phase arrest and apoptosis in MDA-MB-231 breast and A549 lung cancer cells.
Artificial cells, nanomedicine, and biotechnology·2025
Oral Administration of Carotenoid-Rich Dunaliella salina Powder Inhibits Colon Carcinogenesis via Modulation of Wnt/β-catenin Signaling Cascades in a Rat Model.
Applied biochemistry and biotechnology·2024
The Western Australian Mesothelioma Registry: Analysis of 60 years of cases.
Respirology (Carlton, Vic.)·2023
Theranostic signature of tumor-derived exosomes in cancer.
Medical oncology (Northwood, London, England)·2023
A cell-type resolved proton RBE model for potential clinical application.
Medical physics·2026
Adaptive MR-guided whole-pelvic SBRT with or without focal intraprostatic lesion boost for high-risk localized prostate Cancer: Adverse events and longitudinal quality-of-life outcomes.
Clinical and translational radiation oncology·2026
Development and validation of a cumulative risk model and assessment tool for radiation-induced hypothyroidism in head and neck cancer: a multicentre study.
Clinical and translational radiation oncology·2026
Radiation therapy quality assurance (RT QA) of adjuvant fractionated radiotherapy for WHO grade 2 atypical meningioma in the ROAM/EORTC1308 trial.
Clinical and translational radiation oncology·2026